These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
166 related items for PubMed ID: 30521129
1. Particle size and gastrointestinal absorption influence tiotropium pharmacokinetics: a pilot bioequivalence study of PUR0200 and Spiriva HandiHaler. Perry J, Trautman B, Takher-Smith J, Kramer S, Kane K, Silverman M, Tan L, Haughie S, Richter W, Kirkov V, Arsova S, Ward J, Hava DL. Br J Clin Pharmacol; 2019 Mar; 85(3):580-589. PubMed ID: 30521129 [Abstract] [Full Text] [Related]
2. The pharmacokinetics, pharmacodynamics and tolerability of PUR0200, a novel tiotropium formulation, in chronic obstructive pulmonary disease. Singh D, Ravi A, Kane K, Schmalbach T, Hava DL. Br J Clin Pharmacol; 2018 Sep; 84(9):2097-2105. PubMed ID: 29790581 [Abstract] [Full Text] [Related]
5. Bioequivalence of Two Tiotropium Dry Powder Inhalers and the Utility of Realistic Impactor Testing. Gobetti C, Dissanayake S, Shur J, Ganley W, Silva L, Salem I, Najib O, Harb U. J Aerosol Med Pulm Drug Deliv; 2023 Oct; 36(5):257-267. PubMed ID: 37358626 [Abstract] [Full Text] [Related]
8. Evaluation of patients' real-world post-dispensing use and storage environments of tiotropium bromide Respimat® soft mist inhaler on its in vitro dose delivery and lung deposition. Ammari WG, Khalil Mohammad M, Tayyem RF. Pulm Pharmacol Ther; 2019 Oct; 58():101829. PubMed ID: 31352077 [Abstract] [Full Text] [Related]
9. Pharmacokinetic study for the establishment of bioequivalence of two inhalation treatments containing budesonide plus formoterol. Grekas N, Athanassiou K, Papataxiarchou K, Rizea Savu S, Silvestro L. J Pharm Pharmacol; 2014 Dec; 66(12):1677-85. PubMed ID: 25109416 [Abstract] [Full Text] [Related]
10. Equivalent Lung Dose and Systemic Exposure of Budesonide/Formoterol Combination via Easyhaler and Turbuhaler. Lähelmä S, Sairanen U, Haikarainen J, Korhonen J, Vahteristo M, Fuhr R, Kirjavainen M. J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):462-73. PubMed ID: 25757188 [Abstract] [Full Text] [Related]
11. A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter? Dahl R, Kaplan A. BMC Pulm Med; 2016 Oct 11; 16(1):135. PubMed ID: 27724909 [Abstract] [Full Text] [Related]
12. Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate? Hochhaus G, Chen MJ, Kurumaddali A, Schilling U, Jiao Y, Drescher SK, Amini E, Berger SM, Kandala B, Tabulov C, Shao J, Seay B, Abu-Hasan MN, Baumstein SM, Winner L, Shur J, Price R, Hindle M, Wei X, Carrasco C, Sandell D, Oguntimein O, Kinjo M, Delvadia R, Saluja B, Lee SL, Conti DS, Bulitta JB. AAPS J; 2021 Mar 25; 23(3):48. PubMed ID: 33768368 [Abstract] [Full Text] [Related]
17. The impact of patients' real-life environmental temperature and humidity use conditions of tiotropium dry powder inhaler on its aerosol emission characteristics. Ammari WG, Mohammad MK, Tayyem RF. Eur J Pharm Sci; 2019 May 15; 133():137-144. PubMed ID: 30946963 [Abstract] [Full Text] [Related]
20. Pharmacokinetics of Salbutamol Delivered from the Unit Dose Dry Powder Inhaler: Comparison with the Metered Dose Inhaler and Diskus Dry Powder Inhaler. Moore A, Riddell K, Joshi S, Chan R, Mehta R. J Aerosol Med Pulm Drug Deliv; 2017 Jun 15; 30(3):164-172. PubMed ID: 28170282 [Abstract] [Full Text] [Related] Page: [Next] [New Search]